YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
AEON Biopharma Inc ALISO VIEJO, Calif., Aug. 31, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 as a biosimilar to BOTOX® (onabotulinumtoxinA) fo…
ALISO VIEJO, Calif., Aug. 03, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 as a biosimilar to BOTOX® (onabotulinumtoxinA) for therapeutic use t…
Humana upgraded, Las Vegas Sands downgraded: Wall Street's top analyst calls The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as co…
The cervical dystonia market is expected to increase due to an increase in disease prevalence during the forecast period. Additionally, the expected launch of emerging therapies such as ABP-450 (prabotulinumtoxinA) (AEON Biopharma), IPN102…
Key Points Dauntless Investment Group bought 116,863 shares of Innoviva in an estimated trade of $2.52 million last quarter. The quarter-end position value rose by $2.74 million, reflecting both trading and price movements. The post-trade…
- Annual Shareholder Meeting to be held at 10:00 am PT on June 17, 2026 - IRVINE, Calif., April 24, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-45…
* AEON Biopharma (NYSE American: AEON) on Friday said that it had received a notice from NYSE American that it was not in compliance with an additional continued listing standard following its year-end financial results. * The company said…
IRVINE, Calif., April 03, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 (prabotulinumtoxinA) as a biosimilar to BOTOX® (onabotulinumtoxinA) to a…
IRVINE, Calif., April 03, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 (prabotulinumtoxinA) as a biosimilar to BOTOX® (onabotulinumtoxinA) to a…
(RTTNews) - AEON Biopharma, Inc. (AEON), a biopharmaceutical company, announced financial results for the full year 2025, reflecting a net loss compared to a profit in the prior year. In addition, the firm provided a business update. Follo…
– Announced positive initial comparative analytical results, confirming identical amino-acid sequencing and highly similar functional characteristics to BOTOX® – – Reported positive FDA BPD Type 2a meeting, with FDA feedback providing a cl…
(RTTNews) - AEON Biopharma, Inc. (AEON), a biopharmaceutical company that develops ABP-450 as a biosimilar to BOTOX, reported that it held a BPD Type 2a meeting with the FDA in addition to the closure of Daewoong's note exchange following…
IRVINE, Calif., Dec. 19, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company seeking accelerated and full-label U.S. market entry by developing ABP-450 (prabotulinumtox…
- First closing of PIPE resulted in ~$1.79M in proceeds - - FDA BPD Type 2a meeting now scheduled for January 21, 2026 - IRVINE, Calif., Nov. 20, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON)…
* AEON Biopharma press release [https://seekingalpha.com/pr/20308149-aeon-biopharma-reports-third-quarter-2025-results-including-positive-abpminus-450] (AEON [https://seekingalpha.com/symbol/AEON]): Q3 GAAP EPS of -$0.39. * Reported a net…
– FDA Type 2a meeting scheduled for November 19, 2025, to review AEON’s analytical development plan and initial data – – Positive biosimilarity data for ABP-450 confirming identical amino-acid sequencing and highly similar functional chara…
- Combined transactions will strengthen balance sheet and reduce outstanding debt by more than 90% - - $6 million PIPE financing with potential for over $7 million of additional capital via cash-exercise warrants - - Daewoong has entered b…
Key Insights Significant control over Aeon (M) Bhd by public companies implies that the general public has more power to influence management and governance-related decisions Aeon Co., Ltd. owns 52% of the company Institutional ownership i…
– Multiple near-term potential milestones, including anticipated completion of primary structure analysis and select functional analyses in 3Q’25 – – Type 2a meeting with the FDA anticipated in 4Q’25– – Cash runway expected to support oper…
Company Logo The Japanese loyalty market is poised to grow by 15.4% annually, reaching $3.87 billion by 2025. Significant digital integration, e-commerce growth, and mobile payments are fueling this expansion. Key trends include personaliz…
IRVINE, Calif., May 23, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex for the treatment of multiple therapeu…
IRVINE, Calif., May 19, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex for the treatment of multiple therapeu…
– Continue to conduct analytical studies to prepare for a potential Biosimilar Biological Product Development (“BPD”) Type 2a meeting with the FDA in the second half of 2025 – – Pursuing a 351(k) regulatory pathway for ABP-450, which offer…
IRVINE, Calif., April 25, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex for the treatment of multiple therap…
IRVINE, Calif., April 21, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex for the treatment of multiple therap…
IRVINE, Calif., April 21, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex for the treatment of multiple therap…
– Initiated analytical studies in Q4 2024to prepare for a potential Biosimilar Biological Product Development (“BPD”) Type 2a meeting with the FDA in the second half of 2025– – Pursuing a 351(k) regulatory pathway for ABP-450, which offers…
IRVINE, Calif., March 04, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (NYSE: AEON) (the “Company”), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex under a 351(k) biosimilar pathway, today annou…
IRVINE, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (NYSE: AEON) (the “Company”), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex under a 351(k) biosimilar pathway, today announ…
IRVINE, Calif., Feb. 07, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (NYSE: AEON) (the “Company”), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex under a 351(k) biosimilar pathway, today announ…
– Announced topline results from Phase 2 Trial of ABP-450 (prabotulinumtoxinA) for the preventive treatment of episodic migraine that support advancing the program into a pivotal Phase 3 study – – Ongoing Phase 2 trial for the preventive t…
– ABP-450 doses of 150 units and 195 units showed treatment effect of 4.8 days and 5.0 days, respectively, in the mean change from baseline in monthly migraine days (MMD) at weeks 21-24 but did not meet statistical significance vs. placebo…
IRVINE, Calif., Aug. 29, 2023 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON, AEON WS), a clinical-stage biopharmaceutical company focused on developing a proprietary botulinum toxin complex for the treatmen…
IRVINE, Calif., Aug. 24, 2023 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON, AEON WS), a clinical-stage biopharmaceutical company focused on developing a proprietary botulinum toxin complex for the treatmen…
The 7,380,394 AEON shares reflected in the Form 4 filed on August 14th were transferred to limited partners of Strathspey Crown Strathspey Crown did not sell any AEON shares to the public as part of this transaction All shares transferred…
Common stock and warrants of combined company will be listed on the New York Stock Exchange American under the symbols AEONand AEON WS, respectively Phase 2 topline data with ABP-450 for the preventive treatment of episodic migraine is ant…